Carmot Therapeutics Inc.
http://carmot-therapeutics.us/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Carmot Therapeutics Inc.
Roche’s New Obesity Play Shows Early Promise
CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.
Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs
C-suite leaders from Lilly, Roche and J&J spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape.
IQVIA Notes Increasing Share Of Deals Between Smaller Biopharmas
In its 2023 report on global R&D trends for the biopharma sector, IQVIA found a shrinking percentage of deals involving $5bn+ revenue companies; R&D spending among big pharmas is the highest since 2014.
Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects
After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Molecular Diversity
-
Drug Discovery Technologies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice